Плейотропные эффекты нетакимаба у пациентов с псориатическим артритом, спондилитом и сопутствующим метаболическим синдромом или новая возможность контроля массы тела?

Карибова А.К., Ахмедханов С.Ш., Кудаев М.Т., Азизова Е.А. Плейотропные эффекты нетакимаба у пациентов с псориатическим артритом, спондилитом и сопутствующим метаболическим синдромом или новая возможность контроля массы тела? Терапевтический архив. 2024;96(12):1230–1237. DOI: 10.26442/00403660.2024.12.202837

© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.

________________________________________________

Karibova AK, Akhmedkhanov SSh, Kudaev MT, Azizova EA. Pleiotropic effects of netakimab in patients with psoriatic arthritis, spondylitis and comorbid metabolic syndrome or a new opportunity for weight control? Case report. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(12):1230–1237. DOI: 10.26442/00403660.2024.12.202837

Читать PDF

Аннотация

В статье представлены результаты изучения эффективности нетакимаба (Эфлейра) в комплексном лечении пациентов с псориазом, псориатическим артритом, спондилитом и сопутствующим метаболическим синдромом. Исследование включало наблюдения за клиническими проявлениями заболеваний и изменениями после применения нетакимаба. В результате лечения отмечено улучшение не только клинических симптомов, но и показателей метаболического синдрома. У всех 3 пациентов, получавших нетакимаб, замечено снижение активности сакроилеита, сопровождающееся потерей массы тела, что свидетельствует о плейотропном влиянии данного препарата. Описанные клинические случаи являются интересными для ревматологов, дерматологов, эндокринологов, терапевтов, врачей общей практики и иллюстрируют успешное применение нетакимаба как ингибитора интерлейкина-17.

Ключевые слова: псориатический артрит, спондилит, метаболический синдром, коморбидность, интерлейкин-17, нетакимаб, плейотропный эффект нетакимаба, лечение ожирения

________________________________________________

The article presents the results of studying the efficacy of netakimab (Efleira) in the complex treatment of patients with psoriasis, psoriatic arthritis, spondylitis and concomitant metabolic syndrome. The study included observations of clinical manifestations of diseases and changes after the use of netakimab. As a result of treatment, there was an improvement not only in clinical symptoms, but also in the metabolic syndrome parameters. In all 3 patients treated with netakimab, there was a decrease in the activity of sacroileitis, accompanied by weight loss, which indicates pleiotropic effect of this drug. The described clinical cases are of interest to rheumatologists, dermatologists, endocrinologists, therapists, general practitioners, and illustrate the successful use of netakimab as an interleukin-17 inhibitor.

Keywords: psoriatic arthritis, spondylitis, metabolic syndrome, comorbidity, interleukin-17, netakimab, pleiotropic effect of netakimab, treatment of obesity

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. DOI:10.1016/j.autrev.2019.102429
2. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю., и др. Клинико-инструментальная характеристика псориатического артрита у мужчин и женщин. Данные когортного наблюдательного исследования. Терапевтический архив. 2024;96(5):479-85 [Korsakova YL, Korotaeva TV, Loginova EI, et al. Clinical and instrumental characteristics of psoriatic arthritis in men and women. Data from a cohort observational study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(5):479-85 (in Russian)]. DOI:10.26442/00403660.2024.05.202703
3. Zindancı I, Albayrak O, Kavala M, et al. Prevalence of metabolic syndrome in patients with psoriasis. ScientificWorldJournal. 2012;2012:312463. DOI:10.1100/2012/312463
4. Merola JF, Kavanaugh A, Lebwohl MG, et al. Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review. Dermatol Ther (Heidelb). 2022;12(10):2201-26. DOI:10.1007/s13555-022-00790-2
5. Wu JJ, Kavanaugh A, Lebwohl MG, et al. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797-806. DOI:10.1111/jdv.18044
6. Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123. DOI:10.1371/journal.pone.0195123
7. Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-92. DOI:10.1016/j.biopha.2018.02.103
8. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-25. DOI:10.1177/1753944717711379
9. Mohamed SM, Shalaby MA, El-Shiekh RA, et al. Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chemistry Advances. 2023;3:100335. DOI:10.1016/j.focha.2023.100335
10. Schmidleithner L, Thabet Y, Schönfeld E, et al. Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunctio. Immunity. 2019;50(5):1232-48.e14. DOI:10.1016/j.immuni.2019.03.014
11. Hao Y, Zhu YJ, Zou S, et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front Immunol. 2021;12:711060. DOI:10.3389/fimmu.2021.711060
12. Su L, Xu C, Huang H, et al. Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis. Front Immunol. 2024;15:1354593. DOI:10.3389/fimmu.2024.1354593
13. Borska L, Kremlacek J, Andrys C, et al. Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis. Int J Mol Sci. 2017;18(11). DOI:10.3390/ijms18112238
14. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. DOI:10.1159/000250839
15. Рекомендации по ведению больных с метаболическим синдромом Министерства здравоохранения Российской Федерации. М. 2013. Режим доступа: mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf. Ссылка активна на 06.03.2024 [Rekomendatsii po vedeniiu bol'nykh s metabolicheskim sindromom Ministerstva zdravookhraneniia Rossiiskoi Federatsii. Moscow. 2013. Available at: mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf. Accessed: 06.03.2024 (in Russian)].
16. Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R93. DOI:10.1186/ar2477
17. Каратеев Д.Е., Лучихина Е.Л. Современное лечение спондилоартритов: фокус на нетакимаб. Терапевтический архив. 2024;96(5):543-50 [Karateev DE, Luchikhina EL. Current treatment for spondyloarthritis: focus on netakimab. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(5)543-50 (in Russian)]. DOI:10.26442/00403660.2024.05.202794
18. Kaur S, Atri S. Interleukin-17 (IL-17) family cytokines and their receptors in cardiovascular diseases: a potential therapeutic target? Cytokine Growth Factor Rev. 2018;39:137-144.
19. Marzolla V, Armani A, Mammi C, et al. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. Int J Cardiol. 2017;232:233-42. DOI:10.1016/j.ijcard.2017.01.013
20. Jhun JY, Yoon BY, Park MK, et al. Combined treatment with a long-acting form of FGF21 and LXR agonist improves lipid metabolism in ob/ob mice. Int J Obes (Lond). 2016;40(11):1737-44.
21. Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin (Shanghai). 2013;45(9):726-33. DOI:10.1093/abbs/gmt065
22. Herman R, Kravos NA, Jensterle M, et al. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci. 2022;23(3). DOI:10.3390/ijms23031264
23. Colca JR, Scherer PE. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. Mol Metab. 2022;55:101409. DOI:10.1016/j.molmet.2021.101409
24. Bitkin EC, Boyraz M, Taşkın N, et al. Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome. J Clin Res Pediatr Endocrinol.
2013;5(3):164-9. DOI:10.4274/Jcrpe.1020
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. DOI:10.1161/CIRCULATIONAHA.105.169404
26. Mohamed R, Jayakumar C, Chen F, et al. Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis. J Am Soc Nephrol. 2016;27(3):745-65. DOI:10.1681/ASN.2014111136
27. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921-9. DOI:10.1038/nm.2001
28. Wen W, Wan Z, Zhou D, et al. The Amelioration of Insulin Resistance in Salt Loading Subjects by Potassium Supplementation is Associated with a Reduction in Plasma IL-17A Levels. Exp Clin Endocrinol Diabetes. 2017;125(8):571-7. DOI:10.1055/s-0042-101793

________________________________________________

1. Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. DOI:10.1016/j.autrev.2019.102429
2. Korsakova YL, Korotaeva TV, Loginova EI, et al. Clinical and instrumental characteristics of psoriatic arthritis in men and women. Data from a cohort observational study. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(5):479-85 (in Russian). DOI:10.26442/00403660.2024.05.202703
3. Zindancı I, Albayrak O, Kavala M, et al. Prevalence of metabolic syndrome in patients with psoriasis. ScientificWorldJournal. 2012;2012:312463. DOI:10.1100/2012/312463
4. Merola JF, Kavanaugh A, Lebwohl MG, et al. Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review. Dermatol Ther (Heidelb). 2022;12(10):2201-26. DOI:10.1007/s13555-022-00790-2
5. Wu JJ, Kavanaugh A, Lebwohl MG, et al. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797-806. DOI:10.1111/jdv.18044
6. Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123. DOI:10.1371/journal.pone.0195123
7. Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287-92. DOI:10.1016/j.biopha.2018.02.103
8. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-25. DOI:10.1177/1753944717711379
9. Mohamed SM, Shalaby MA, El-Shiekh RA, et al. Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chemistry Advances. 2023;3:100335. DOI:10.1016/j.focha.2023.100335
10. Schmidleithner L, Thabet Y, Schönfeld E, et al. Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunctio. Immunity. 2019;50(5):1232-48.e14. DOI:10.1016/j.immuni.2019.03.014
11. Hao Y, Zhu YJ, Zou S, et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front Immunol. 2021;12:711060. DOI:10.3389/fimmu.2021.711060
12. Su L, Xu C, Huang H, et al. Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis. Front Immunol. 2024;15:1354593. DOI:10.3389/fimmu.2024.1354593
13. Borska L, Kremlacek J, Andrys C, et al. Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis. Int J Mol Sci. 2017;18(11). DOI:10.3390/ijms18112238
14. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44. DOI:10.1159/000250839
15. Rekomendatsii po vedeniiu bol'nykh s metabolicheskim sindromom Ministerstva zdravookhraneniia Rossiiskoi Federatsii. Moscow. 2013. Available at: mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf. Accessed: 06.03.2024 (in Russian).
16. Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R93. DOI:10.1186/ar2477
17. Karateev DE, Luchikhina EL. Current treatment for spondyloarthritis: focus on netakimab. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2024;96(5)543-50 (in Russian). DOI:10.26442/00403660.2024.05.202794
18. Kaur S, Atri S. Interleukin-17 (IL-17) family cytokines and their receptors in cardiovascular diseases: a potential therapeutic target? Cytokine Growth Factor Rev. 2018;39:137-144.
19. Marzolla V, Armani A, Mammi C, et al. Essential role of ICAM-1 in aldosterone-induced atherosclerosis. Int J Cardiol. 2017;232:233-42. DOI:10.1016/j.ijcard.2017.01.013
20. Jhun JY, Yoon BY, Park MK, et al. Combined treatment with a long-acting form of FGF21 and LXR agonist improves lipid metabolism in ob/ob mice. Int J Obes (Lond). 2016;40(11):1737-44.
21. Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin (Shanghai). 2013;45(9):726-33. DOI:10.1093/abbs/gmt065
22. Herman R, Kravos NA, Jensterle M, et al. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci. 2022;23(3). DOI:10.3390/ijms23031264
23. Colca JR, Scherer PE. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. Mol Metab. 2022;55:101409. DOI:10.1016/j.molmet.2021.101409
24. Bitkin EC, Boyraz M, Taşkın N, et al. Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome. J Clin Res Pediatr Endocrinol.
2013;5(3):164-9. DOI:10.4274/Jcrpe.1020
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. DOI:10.1161/CIRCULATIONAHA.105.169404
26. Mohamed R, Jayakumar C, Chen F, et al. Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis. J Am Soc Nephrol. 2016;27(3):745-65. DOI:10.1681/ASN.2014111136
27. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921-9. DOI:10.1038/nm.2001
28. Wen W, Wan Z, Zhou D, et al. The Amelioration of Insulin Resistance in Salt Loading Subjects by Potassium Supplementation is Associated with a Reduction in Plasma IL-17A Levels. Exp Clin Endocrinol Diabetes. 2017;125(8):571-7. DOI:10.1055/s-0042-101793

Авторы

А.К. Карибова*¹, С.Ш. Ахмедханов², М.Т. Кудаев², Е.А. Азизова¹

¹ГБУ Республики Дагестан «Городская клиническая больница», Махачкала, Россия;
²ФГБОУ ВО «Дагестанский государственный медицинский университет» Минздрава России, Махачкала, Россия
*solomon687@gmail.com

________________________________________________

Alida K. Karibova*¹, Seypula Sh. Akhmedkhanov², Magomed T. Kudaev², Ekaterina A. Azizova¹

¹City Clinical Hospital, Makhachkala, Russia;
²Dagestan State Medical University, Makhachkala, Russia
*solomon687@gmail.com

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.